Owners of ANZ Group Holdings Ltd (ASX: ANZ) shares may not have seen a lot of net profit growth over the past decade, but investors may like to know what analysts are expecting of the ASX bank share in the coming two annual results and how that plays into the valuation.

Profit growth is not guaranteed, of course, but ANZ is facing somewhat challenging conditions, with loan demand facing headwinds amid taxation changes and higher interest rates.

But, at the same time, borrowers may be less reliable during this period of economic uncertainty and higher interest rates.

Despite that, shareholders will be pleased to know that the ASX bank share is predicted to grow earnings in the coming annual FY26 result. A projection is not a guarantee of growth, though.

FY26

The ASX bank share’s 2026 financial year finishes in September 2026, so there is still more than a month to go for ANZ.

But, the latest update from the bank showed further progress by the business.

Its quarterly cash profit of $1.9 billion showed 2% year-over-year growth. Net loans and advances were flat year-over-year at $846 billion, though there was an increase in constant currency terms.

The bank also reported that its cost-to-income ratio improved by 155 basis points (1.55%) year-over-year to 49.66%.

ANZ won’t be able to cut costs every reporting period to grow earnings, but it made a sizeable difference in the FY26 third quarter. Operating income for the bank actually declined by 1% year-over-year, while operating expenses improved by 4%. That helped profit before provisions increase 3% to $2.8 billion.

It was a 6% rise in the provision charge to $102 million and a 4% rise in the income tax expense to $819 million that meant the cash profit growth was slower than the profit before provisions growth. Profit is important for supporting ANZ shares.

Analysts expect the ASX bank share’s earnings per share (EPS) to rise to $2.566 in the 2026 financial year, according to Commsec.

FY27

There are a number of things that ANZ is working on to improve its operations in the coming years, including in FY27.

First, ANZ wants to embed its new leadership team and continue to drive a cultural reset.

Second, the ASX bank share wants to integrate Suncorp Bank faster to deliver value.

Third, ANZ wants to accelerate the delivery of its single customer digital front-end.

Fourth, it wants to reduce duplication and simplify the organisation. It noted that 84% of 3,500 announced roles exited the bank by the end of June 2026. Around of 73% of estimated gross cost savings of $875 million in FY26 were realised by the end of June 2026.

Fifth, it wants to enhance non-financial risk management to improve the ASX bank share’s resilience.

The projection on Commsec suggests the business could see EPS slightly fall to $2.55 in FY27.

Therefore, ANZ’s profit isn’t likely to do much after FY26, so there could be better ASX shares to consider.

The post Here’s the earnings forecast out to 2027 for ANZ shares appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: ANZ Bank, Iress, and JB Hi-Fi shares
• Buy, hold, sell: Aristocrat, Telstra, ANZ shares
• These ASX 200 shares could generate $10,000 per year in passive income
• Why I’d buy these 2 ASX ETFs for $10,000 a year in passive income
• 8 ASX 200 shares with fresh buy ratings this week

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus after the company reported half-year revenue up 22% to US$477 million and a strong gross margin improvement to 55%. Adjusted EBITDA surged 146% year-on-year to US$52 million.

What did Telix Pharmaceuticals report?

• Revenue rose 22% year-on-year to US$477 million, tracking to the upper end of FY26 guidance.
• Gross margin climbed to 55%, with Precision Medicine segment margin at 65%.
• Adjusted EBITDA came in at US$52 million, up 146% on the prior year.
• Profit after tax was US$38 million, including a US$40 million payment from Regeneron.
• Group R&D investment was US$124 million, mainly supporting late-stage programs.
• Positive operating cash flow of US$23 million and cash balance of US$252 million at 30 June 2026.

What else do investors need to know?

Telix announced a new strategic collaboration with Regeneron to develop and commercialise next-generation radiopharmaceutical therapies, contributing US$40 million in other income this half. The company also completed refinancing of its convertible bond structure with a new US$600 million issue due 2031.

Operationally, the Precision Medicine segment drove growth with flagship products Illuccix and Gozellix gaining market share. Key clinical milestones were achieved, including enrolment completion for late-stage trials and regulatory progress in the US, China, Europe, and Japan. Telix is also expanding its global manufacturing footprint with new and upgraded facilities in Australia, Belgium, Japan, and the US.

What did Telix Pharmaceuticals management say?

Managing Director and Group CEO, Dr Christian Behrenbruch, said:

Telix delivered an outstanding first half, with strong revenue growth, market share gains and significant progress across clinical and regulatory milestones. Our strengthened balance sheet is enabling increased investment in late-stage programs, including ProstACT Global, market expansion opportunities within our precision medicine portfolio and manufacturing and supply chain capabilities that differentiate Telix. With multiple near-term catalysts, we enter the second half with strong momentum and confidence.

What’s next for Telix Pharmaceuticals?

Telix reaffirmed FY26 revenue and other income guidance above US$1 billion, with R&D expenditure expected between US$230 million and US$270 million. The company expects ongoing clinical trial readouts and regulatory submissions in key territories later in the year.

Strategically, Telix will leverage its expanded manufacturing capacity and commercial partnerships to support commercial growth and pipeline advancement. The new at-the-market equity facility is intended to provide flexible access to capital to underpin future expansion, subject to regulatory approvals.

Telix Pharmaceuticals share price snapshot

The Telix Pharmaceuticals share price has recorded a small decline over the past 12 months, compared with a 1.5% gain from the S&P/ASX 200 index (ASX: XJO).

View Original Announcement

The post Telix Pharmaceuticals delivers robust half-year earnings and pipeline progress appeared first on The Motley Fool Australia.

More reading

• These are the 10 most shorted ASX shares
• These are the 10 most shorted ASX shares
• After rocketing 24% last week, what are experts saying about these red hot ASX shares?
• Here are the top 10 ASX 200 shares today
• Which are the 10 most shorted ASX shares?

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Autosports Group Ltd (AS:X ASG) share price is in focus today after the prestige car retailer posted record full-year revenue of $3.19 billion and normalised profit before tax up 11.1%.

What did Autosports Group report?

• Record FY26 revenue of $3.19 billion, up 11.9% year on year
• Gross profit reached $589.7 million, up 15% from FY25
• Normalised NPBT of $53.5 million, up 11.1%
• New vehicle order write climbed 20% compared to the prior year
• Order bank soared 290% since 30 June 2025
• Vehicle service and parts revenue increased by 16% and 22%, respectively

What else do investors need to know?

Autosports Group’s core prestige and luxury segments stayed resilient despite challenging market conditions, supported by strong demand for new energy and electric vehicles. The group faced stock shortages in the final quarter as accelerated demand for electric models outpaced inventory, but it maintained gross margins at 18.5%.

To fund growth and expand its network, the company increased its Syndicated Facility Agreement by $85 million to $435 million, extending maturities and relaxing some covenants. Meanwhile, new greenfield dealerships are scheduled to open in Sydney, and a key property acquisition in Canberra will strengthen its ACT operations.

What did Autosports Group management say?

Chief Executive Officer Nick Pagent said:

Our record performance reflects our disciplined growth strategy and commitment to representing brands that are future-ready. The surge in electric vehicle demand puts us in a strong position as new supply arrives.

What’s next for Autosports Group?

Autosports Group remains upbeat as it enters FY27 with new dealership launches, including Mercedes-Benz Southport and new luxury EV brands Omoda Jaecoo and XPENG in Sydney. The acquisition in Canberra underpins further expansion plans.

Management expects the record order bank to begin unwinding in the second half of FY27 as new electric vehicle supply finally meets strong demand. Additional growth is anticipated from newly acquired businesses and continued roll-out of new electric and luxury vehicles, positioning Autosports Group well in the evolving automotive market.

Autosports Group share price snapshot

Over the past 12 months, Autosports Group shares have declined 46%, trailing the All Ordinaries Index (ASX: XAO), which has risen 1% over the same period.

View Original Announcement

The post Autosports Group posts record revenue and surging EV orders in FY26 appeared first on The Motley Fool Australia.

More reading

• MA Financial delivers record 1H26 earnings and lifts dividend
• Sonic Healthcare share price in focus on FY26 profit jump and digital push
• Ridley: FY26 profit jumps on fertiliser boost
• IPH Ltd FY26 earnings: resilient profit growth and higher dividend
• 2 ASX shares tipped to grow 40% or more in the next 12 months

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.